- Home
- HCWB
HCWB
HCW Biologics Inc.
as 06-26-2025 4:00pm EST
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | MIRAMAR |
| Market Cap: | 16.1M | IPO Year: | 2021 |
| Target Price: | $35.00 | AVG Volume (30 days): | 66.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -24.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.05 - $100.80 | Next Earning Date: | 08-13-2025 |
| Revenue: | $1,445,145 | Revenue Growth: | -63.20% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of HCW Biologics Inc. (HCWB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GARRETT SCOTT T | HCWB | Director | May 16 '25 | Buy | $7.45 | 13,423 | $100,001.35 | 25,505 | |
| Winer Gary M | HCWB | Director | May 16 '25 | Buy | $7.45 | 1,342 | $9,997.90 | 4,075 | |
| Wong Hing C | HCWB | Chief Executive Officer | May 16 '25 | Buy | $7.45 | 8,054 | $60,002.30 | 501,911 | |
| GARRETT SCOTT T | HCWB | Director | May 7 '25 | Buy | $26.00 | 5,385 | $140,010.00 | 25,505 | |
| Greene Rick S. | HCWB | Director | May 7 '25 | Buy | $26.00 | 962 | $25,012.00 | 2,066 | |
| Flowers Lee | HCWB | SVP of Business Development | May 7 '25 | Buy | $26.00 | 962 | $25,012.00 | 5,720 | |
| Byam Rebecca | HCWB | Chief Financial Officer | May 7 '25 | Buy | $26.00 | 8,462 | $220,012.00 | 43,010 | |
| Wong Hing C | HCWB | Chief Executive Officer | May 7 '25 | Buy | $26.00 | 92,500 | $2,405,000.00 | 501,911 |
Latest HCW Biologics Inc. News
HCWB Breaking Stock News: Dive into HCWB Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 hours ago
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
GlobeNewswire
a day ago
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
GlobeNewswire
23 days ago
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
GlobeNewswire
a month ago
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
MT Newswires
a month ago
HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge
GlobeNewswire
a month ago
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
MT Newswires
2 months ago
Hcw Biologics Insider Bought Shares Worth $2,405,000, According to a Recent SEC Filing
MT Newswires
3 months ago
HCW Biologics to Implement 1-for-40 Reverse Stock Split
Compare HCWB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCWB HCW Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.